While the FDA-approved indication of lorlatinib is for advanced ALK-positive (ALK+) NSCLC, the NCCN guidelines include lorlatinib as a treatment option for patients with ROS1+ NSCLC and progression on a prior TKI based on these phase I/II trial data.17,41. Here, ROS1 is linked to non-small cell lung carcinoma.